Advertisement

Osteoblastic Factors in Prostate Cancer Bone Metastasis

  • Song-Chang Lin
  • Li-Yuan Yu-Lee
  • Sue-Hwa Lin
Cancer-induced Musculoskeletal Diseases (J Sterling and E Keller, section editors)
Part of the following topical collections:
  1. Topical Collection on Cancer-induced Musculoskeletal Diseases

Abstract

Purpose of Review

Prostate cancer bone metastasis is the lethal progression of the disease. The disease frequently presents with osteoblastic lesions in bone. The tumor-induced bone can cause complications that significantly hamper the quality of life of patients. A better understanding of how prostate cancer induces aberrant bone formation and how the aberrant bone affects the progression and treatment of the disease may improve the therapies for this disease.

Recent Findings

Prostate cancer-induced bone was shown to enhance tumor growth and confer therapeutic resistance in bone metastasis. Clinically, Radium-223, an alpha emitter that selectively targets bone, was shown to improve overall survival in patients, supporting a role of tumor-induced bone in prostate cancer progression in bone. Recently, it was discovered that PCa-induced aberrant bone formation is due, in part, from tumor-associated endothelial cells that were converted into osteoblasts through endothelial-to-osteoblast (EC-to-OSB) conversion by tumor-secreted BMP4.

Summary

The unique bone-forming phenotype of prostate cancer bone metastasis plays a role in prostate cancer progression in bone and therapy resistance. Therapies that incorporate targeting the tumor-induced osteoblasts or EC-to-OSB conversion mechanism may reduce tumor-induced bone formation and improve therapy outcomes.

Keywords

Bone metastasis Prostate cancer Tumor-induced bone Osteocrines EC-to-OSB conversion 

Notes

Funding

This work was supported by grants from the NIH R01CA174798, NIH 5P50CA140388, NIH P30CA16672 Core grant to M.D. Anderson Cancer Center; Cancer Prevention Research Institute of Texas CPRIT RP150179; and Sister Institute Network Fund at U. Texas M.D. Anderson Cancer Center.

Compliance with Ethical Standards

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Conflict of Interest

Song-Chang Lin, Li-Yuan Yu-Lee, and Sue-Hwa Lin declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Hensel J, Thalmann GN. Biology of bone metastases in prostate cancer. Urology. 2016;92:6–13.CrossRefPubMedGoogle Scholar
  2. 2.
    Olechnowicz SW, Edwards CM. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res. 2014;74(6):1625–31.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Buenrostro D, Mulcrone PL, Owens P, Sterling JA. The bone microenvironment: a fertile soil for tumor growth. Curr Osteoporos Rep. 2016;14(4):151–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008;180(3):1154–60.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Roodman GD. Mechanisms of bone metastasis. Discov Med. 2004;4(22):144–8.PubMedGoogle Scholar
  6. 6.
    Zhang S, Wang J, Bilen MA, Lin SH, Stupp SI, Satcher RL. Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clin Exp Metastasis. 2009;26(8):993–1004.CrossRefPubMedGoogle Scholar
  7. 7.
    Li Y, Sikes RA, Malaeb BS, Yeung F, Law A, Graham SE, et al. Osteoblasts can stimulate prostate cancer growth and transcriptionally down-regulate PSA expression in cell line models. Urol Oncol. 2011;29(6):802–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 1991;51(14):3753–61.PubMedGoogle Scholar
  9. 9.
    Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, et al. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008;68(23):9996–10003.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008;118(8):2697–710.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    • Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, et al. BMP4 promotes prostate tumor growth in bone through Osteogenesis. Cancer Res. 2011;71(15):5194–203. This study demonstrates that osteogenesis is necessary for prostate tumor growth in bone. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ozdemir BC, Hensel J, Secondini C, Wetterwald A, Schwaninger R, Fleischmann A, et al. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches. PLoS One. 2014;9(12):e114530.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    • Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. First clinical study that demonstrates that targeting tumor-induced aberrant bone by radium-223 improved overall survival in men with castration-resistant prostate cancer and bone metastases. CrossRefPubMedGoogle Scholar
  14. 14.
    Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011;103(22):1665–75.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Krzeszinski JY, Wan Y. New therapeutic targets for cancer bone metastasis. Trends Pharmacol Sci. 2015;36(6):360–73.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Thoreson GR, Gayed BA, Chung PH, Raj GV. Emerging therapies in castration resistant prostate cancer. Can J Urol. 2014;21(2 Supp 1):98–105.PubMedGoogle Scholar
  17. 17.
    Ramos P, Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2015;34(28):3617–26.CrossRefPubMedGoogle Scholar
  18. 18.
    Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31(4):412–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013;19(11):3088–94.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff KM, Aftab DT, et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res. 2014;20(3):617–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee C, Whang YM, Campbell P, Mulcrone PL, Elefteriou F, Cho SW, et al. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. Cancer Lett. 2018;414:205–13.CrossRefPubMedGoogle Scholar
  23. 23.
    • Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, et al. Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer. Cancer Res. 2015;75(22):4949–59. This study shows that paracrine factors secreted from tumor-induced bone can confer resistance to therapies for prostate cancer bone metastasis. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sakamoto S, McCann RO, Dhir R, Kyprianou N. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res. 2010;70(5):1885–95.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kwakwa KA, Sterling JA. Integrin alphavbeta3 signaling in tumor-induced bone disease. Cancers (Basel). 2017;9(7).Google Scholar
  26. 26.
    Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, et al. Targeting constitutively activated beta1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013;11(4):405–17.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Jahangiri A, Aghi MK, Carbonell WS. Beta1 integrin: critical path to antiangiogenic therapy resistance and beyond. Cancer Res. 2014;74(1):3–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem. 2004;91(1):151–60.CrossRefPubMedGoogle Scholar
  29. 29.
    van Meeteren LA, ten Dijke P. Regulation of endothelial cell plasticity by TGF-beta. Cell Tissue Res. 2012;347(1):177–86.CrossRefPubMedGoogle Scholar
  30. 30.
    Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005;65(18):8274–85.CrossRefPubMedGoogle Scholar
  31. 31.
    Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, et al. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics. 2015;14(3):471–83.CrossRefPubMedGoogle Scholar
  32. 32.
    Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003;97(3 Suppl):779–84.CrossRefPubMedGoogle Scholar
  33. 33.
    Marie PJ, Debiais F, Hay E. Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol Histopathol. 2002;17(3):877–85.PubMedGoogle Scholar
  34. 34.
    Bang C, Thum T. Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol. 2012;44(11):2060–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Hood JL, Pan H, Lanza GM, Wickline SA. Consortium for translational research in advanced I, nanomedicine. Paracrine induction of endothelium by tumor exosomes. Lab Investig. 2009;89(11):1317–28.CrossRefPubMedGoogle Scholar
  36. 36.
    Greening DW, Gopal SK, Mathias RA, Liu L, Sheng J, Zhu HJ, et al. Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Semin Cell Dev Biol. 2015;40:60–71.CrossRefPubMedGoogle Scholar
  37. 37.
    Zhang HG, Grizzle WE. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol. 2014;184(1):28–41.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hashimoto K, Ochi H, Sunamura S, Kosaka N, Mabuchi Y, Fukuda T, et al. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc Natl Acad Sci U S A. 2018;115:2204–9.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5(1):21–8.CrossRefPubMedGoogle Scholar
  40. 40.
    • Lin SC, Lee YC, Yu G, Cheng CJ, Zhou X, Chu K, et al. Endothelial-to-osteoblast conversion generates osteoblastic metastasis of prostate cancer. Developmental Cell. 2017;41(5):467–80 e3. This study demonstrates that one of the mechanisms that leads to osteoblastic bone metastasis is through tumor-induced endothelial-to osteoblast conversion. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc). 2002;38(2):91–102.CrossRefGoogle Scholar
  42. 42.
    Sottnik JL, Keller ET. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med. 2013;13(4):626–39.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ortiz A, Lin SH. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum? Recent Results Cancer Res. 2012;192:225–33.CrossRefPubMedGoogle Scholar
  44. 44.
    Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355(9213):1428–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Sano M, Kushida K, Takahashi M, Ohishi T, Kawana K, Okada M, et al. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer. 1994;70(4):701–3.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol. 1996;156(5):1691–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59–69.CrossRefPubMedGoogle Scholar
  48. 48.
    Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991;68(1):74–80.CrossRefPubMedGoogle Scholar
  49. 49.
    Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(15):2436–42.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23(31):7904–10.CrossRefPubMedGoogle Scholar
  52. 52.
    Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392–400.CrossRefPubMedGoogle Scholar
  53. 53.
    Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738–46.CrossRefPubMedGoogle Scholar
  54. 54.
    Vapiwala N, Glatstein E. Fighting prostate cancer with radium-223--not your Madame’s isotope. N Engl J Med. 2013;369(3):276–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Translational Molecular PathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of MedicineBaylor College of MedicineHoustonUSA
  3. 3.Department of Genitourinary Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations